C4 Therapeutics (CCCC) AI Stock Analysis

• Market Cap: $175.08M
• Dividend Yield: N/A
• Average Volume (3M): 1.76M
• Price to Earnings (P/E): ―
• Beta (1Y): 3.45
• Revenue Growth: 16.55%
• EPS Growth: 16.73%
• Country: US
• Employees: 110
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -0.37
• Shares Outstanding: 71,170,815
• 10 Day Avg. Volume: 2,154,337
• 30 Day Avg. Volume: 1,762,713
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.29
• Enterprise Value/Revenue: -1.80
• Enterprise Value/Gross Profit: -2.09
• Enterprise Value/Ebitda: 0.45
• 1Y Price Target: $4.75
• Price Target Upside: 66.08% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 54 Neutral
• Price Target: $2.50 ▼(-12.59% Downside)

C4 Therapeutics' overall stock score is primarily impacted by its financial performance, which shows significant challenges with profitability and cash flow. While technical analysis indicates bullish momentum, the high volatility and negative valuation metrics weigh heavily on the stock's attractiveness. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Partnership Opportunities

Management intends to partner cemsi to maximize value, which could result in a rally of shares upon an announcement.

Product Potential

CFT1946 has the potential to replace BRAF inhibitors and be CCCC's first wholly-owned commercial product.

Valuation

The company's valuation at an EV of ~$50MM suggests a significant opportunity for growth, as the market currently assigns no value to certain promising programs.

Negative Factors

Market Competition

Competitors in the market could challenge the potential growth of CFT1946 and its ability to replace existing BRAF inhibitors.

Regulatory Uncertainty

The process of determining the dosing regimen for cemsi highlights challenges related to regulatory approval and competitive profiling.

C4 Therapeutics Business Overview & Revenue Model

Company Description

C4 Therapeutics (CCCC) is a biotechnology company focused on pioneering a new class of targeted protein degradation (TPD) medicines to treat cancer and other diseases. Operating within the biopharmaceutical sector, the company utilizes its proprietary technology platform, TORPEDO, to develop small-molecule drugs that selectively degrade disease-causing proteins. By harnessing the body's natural protein disposal system, C4 Therapeutics aims to address challenging targets that have been deemed undruggable by traditional approaches.

How the Company Makes Money

C4 Therapeutics generates revenue primarily through strategic collaborations and partnerships with other biotechnology and pharmaceutical companies. These agreements typically involve upfront payments, milestone payments, and potential royalties based on the successful development and commercialization of TPD therapies. The company's partnerships often focus on leveraging its TORPEDO platform to advance novel drug candidates through various stages of clinical development. While C4 Therapeutics is actively engaged in research and development activities, its revenue model is heavily reliant on these collaborations to fund its operations and growth initiatives.

C4 Therapeutics Financial Statement Overview

Summary

C4 Therapeutics faces significant financial challenges, with persistent losses impacting profitability and cash flows. While the balance sheet remains relatively stable, the company needs to address its operational inefficiencies to improve financial health. Strategic adjustments may be necessary to enhance revenue generation and cost management to achieve sustainable growth.

Income Statement

The income statement reveals a company struggling with profitability. The TTM (Trailing-Twelve-Months) shows negative EBIT and net income, indicating operational challenges. Although there's a modest revenue growth of 11.8% from the previous year, margins remain negative, suggesting ongoing difficulties in cost management or revenue generation.

Balance Sheet

The balance sheet shows a reasonable equity ratio of 61.07%, indicating a solid capital structure with more assets funded by equity. However, the debt-to-equity ratio of 0.33 reflects manageable leverage but could pose risks if financial performance does not improve. Return on equity remains negative due to ongoing losses.

Cash Flow

Cash flow analysis indicates issues with cash generation, as both operating and free cash flows are negative in the TTM (Trailing-Twelve-Months). The operating cash flow to net income ratio is negative, pointing to inefficiencies in converting sales into cash, while free cash flow is deteriorating, signaling cash management challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	27.78M	35.58M	20.76M	31.10M	45.78M	33.20M
Gross Profit	23.95M	35.58M	-96.95M	23.52M	42.88M	-44.27M
EBITDA	-112.50M	-103.37M	-122.10M	-124.28M	-78.84M	-62.89M
Net Income	-111.58M	-105.32M	-132.49M	-126.50M	-86.04M	-66.33M
Balance Sheet
Total Assets	296.53M	349.60M	376.45M	430.84M	506.76M	400.14M
Cash, Cash Equivalents and Short-Term Investments	214.55M	244.90M	253.68M	337.12M	309.28M	371.69M
Total Debt	62.92M	65.76M	70.98M	87.15M	42.88M	22.92M
Total Liabilities	122.46M	133.62M	130.34M	141.61M	117.16M	119.35M
Stockholders Equity	174.06M	215.99M	246.11M	289.23M	389.61M	280.79M
Cash Flow
Free Cash Flow	-87.58M	-65.34M	-108.55M	-111.44M	-88.24M	-67.90M
Operating Cash Flow	-87.41M	-65.16M	-106.84M	-105.94M	-86.97M	-67.25M
Investing Cash Flow	81.88M	-51.27M	158.35M	58.42M	-189.34M	-190.50M
Financing Cash Flow	10.57M	45.34M	45.49M	1.15M	171.40M	348.93M

C4 Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.86
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCCC, the sentiment is Positive. The current price of 2.86 is above the 20-day moving average (MA) of 2.29, above the 50-day MA of 1.95, and above the 200-day MA of 2.72, indicating a bullish trend. The MACD of 0.16 indicates Negative momentum. The RSI at 67.97 is Neutral, neither overbought nor oversold. The STOCH value of 57.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CCCC.

C4 Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$19.37B	4.62	-4.00%	3.28%	11.14%	-17.52%
CCCC	54 Neutral	$175.08M	―	-52.99%	―	16.55%	16.73%
ZNTL	46 Neutral	$114.70M	―	-49.55%	―	-33.76%	17.10%
ZURA	43 Neutral	$107.93M	―	-46.33%	―	―	-50.20%
CLYM	41 Neutral	$128.75M	―	-22.92%	―	―	67.69%
KYTX	36 Underperform	$151.79M	―	-61.29%	―	―	-39.69%
VOR	33 Underperform	$271.10M	―	-125.43%	―	―	-686.13%

C4 Therapeutics Corporate Events

C4 Therapeutics Completes Phase 1 Trial Enrollment

On August 7, 2025, C4 Therapeutics announced the completion of enrollment and dose escalation for its Phase 1 trial of cemsidomide in multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL), showing promising response rates. The company plans to align with the FDA on a Phase 2 dose by the end of 2025 and initiate registrational development in early 2026, focusing on MM treatment. Financially, C4T reported a decrease in revenue for Q2 2025 compared to the previous year, primarily due to a previous milestone payment, but maintained a strong cash position expected to fund operations until mid-2027.

C4 Therapeutics Holds Annual Stockholders Meeting

On June 18, 2025, C4 Therapeutics held its Annual Meeting of Stockholders, where key decisions were made regarding the company’s governance and operational strategies. Stockholders elected three Class II directors, approved executive compensation, ratified KPMG LLP as the independent auditor, and agreed to amend the company’s certificate of incorporation to double the authorized shares of common stock, reflecting strategic growth ambitions.